
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3743986/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology, 2009, 27, 6199-6206.	0.8	4,126
2	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Journal of Clinical Oncology, 2001, 19, 3635-3648.	0.8	2,462
3	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. Journal of Clinical Oncology, 2001, 19, 3622-3634.	0.8	2,394
4	Sentinel-Node Biopsy or Nodal Observation in Melanoma. New England Journal of Medicine, 2006, 355, 1307-1317.	13.9	1,679
5	Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492.	157.7	1,662
6	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. New England Journal of Medicine, 2014, 370, 599-609.	13.9	1,203
7	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	13.9	1,087
8	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	13.7	1,068
9	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, 1239-1246.	0.8	942
10	Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma. Annals of Surgery, 1999, 230, 453.	2.1	694
11	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2012, 30, 2678-2683.	0.8	691
12	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	13.5	688
13	Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery, 2005, 242, 302-313.	2.1	632
14	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	3.2	589
15	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	7.7	547
16	Cutaneous melanoma. Lancet, The, 2005, 365, 687-701.	6.3	511
17	Experience with 998 cutaneous melanomas of the head and neck over 30 years. American Journal of Surgery, 1991, 162, 310-314.	0.9	471
18	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research, 2014, 20, 1965-1977.	3.2	447

#	Article	IF	CITATIONS
19	Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Research, 1995, 5, 255-260.	0.6	430
20	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 3242-3249.	3.2	405
21	A new American Joint Committee on Cancer staging system for cutaneous melanoma. , 2000, 88, 1484-1491.		389
22	Determinants of Outcome in Melanoma Patients With Cerebral Metastases. Journal of Clinical Oncology, 2004, 22, 1293-1300.	0.8	389
23	Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. Journal of Clinical Oncology, 2010, 28, 2452-2459.	0.8	374
24	Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer, 2003, 97, 1488-1498.	2.0	372
25	<scp>PD</scp> â€L1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€ <scp>PD</scp> â€1/ <scp>PD</scp> â€ <scp>L</scp> 1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	1.5	356
26	Psychological responses of patients receiving a diagnosis of cancer. Annals of Oncology, 2003, 14, 48-56.	0.6	347
27	An Evidence-based Staging System for Cutaneous Melanoma. Ca-A Cancer Journal for Clinicians, 2004, 54, 131-149.	157.7	322
28	Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. Journal of Clinical Oncology, 2011, 29, 2199-2205.	0.8	313
29	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ⁻ve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	3.2	297
30	Desmoplastic and desmoplastic neurotropic melanoma. Cancer, 1998, 83, 1128-1135.	2.0	295
31	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	5.8	295
32	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology, 2013, 37, 61-65.	2.1	289
33	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.4	270
34	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	1.3	269
35	Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. American Journal of Surgery, 1995, 170, 461-466.	0.9	268
36	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, The, 2012, 13, 589-597.	5.1	253

#	Article	IF	CITATIONS
37	Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 Journal of	0.8	240
38	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	9.4	221
39	The Role of Whole-Body Positron Emission Tomography With [18F]Fluorodeoxyglucose in Identifying Operable Colorectal Cancer Metastases to the Liver. Archives of Surgery, 1996, 131, 703.	2.3	216
40	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
41	Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy11No competing interests declared Journal of the American College of Surgeons, 1999, 189, 195-204.	0.2	202
42	Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. , 1998, 14, 238-247.		194
43	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	3.2	192
44	Noise pollution in the operating theatre. Lancet, The, 1990, 335, 891-894.	6.3	186
45	The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up. Annals of Surgical Oncology, 2004, 11, 426-433.	0.7	180
46	The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). Annals of Surgical Oncology, 2010, 17, 3324-3329.	0.7	177
47	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1049-1060.	5.1	173
48	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 2007, 20, 416-426.	2.9	169
49	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	5.8	165
50	Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Research, 1996, 6, 325-330.	0.6	164
51	Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study. Annals of Surgical Oncology, 2006, 13, 809-816.	0.7	161
52	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1713-1742.	3.3	159
53	Subungual Melanoma. American Journal of Surgical Pathology, 2007, 31, 1902-1912.	2.1	157
54	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 2013, 133, 509-517.	0.3	156

#	Article	IF	CITATIONS
55	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of Surgical Oncology, 2012, 19, 2547-2555.	0.7	155
56	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
57	Interval Nodes. Archives of Surgery, 2000, 135, 1168.	2.3	154
58	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2011, 131, 1631-1638.	0.3	153
59	Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. Journal of Nuclear Medicine, 1993, 34, 1435-40.	2.8	152
60	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 2017, 30, 1666-1676.	2.9	150
61	Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. Journal of Clinical Oncology, 2011, 29, e237-e240.	0.8	148
62	Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas. American Journal of Surgical Pathology, 2003, 27, 1571-1576.	2.1	147
63	Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience. Annals of Surgical Oncology, 2008, 15, 3003-3013.	0.7	146
64	Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases. Annals of Surgical Oncology, 2013, 20, 3961-3968.	0.7	146
65	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the United States of America, 2015, 112, 10995-11000.	3.3	146
66	Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 2002, 20, 4181-4190.	0.8	144
67	Surgical Resection for Metastatic Melanoma to the Liver. Archives of Surgery, 2001, 136, 950.	2.3	142
68	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. Clinical Cancer Research, 2008, 14, 638-645.	3.2	141
69	Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Research, 1994, 4, 395-399.	0.6	135
70	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 2011, 5, 124-136.	2.1	135
71	Sentinel node biopsy and standard of care for melanoma. Journal of the American Academy of Dermatology, 2009, 60, 872-875.	0.6	132
72	Desmoplastic neurotropic melanoma. Cancer, 2008, 113, 2770-2778.	2.0	131

#	Article	IF	CITATIONS
73	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 475-481.	0.7	131
74	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	5.1	131
75	Patterns of lymphatic drainage from the skin in patients with melanoma. Journal of Nuclear Medicine, 2003, 44, 570-82.	2.8	128
76	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. European Journal of Cancer, 2014, 50, 111-120.	1.3	127
77	MORPHOMETRIC ANALYSIS OF CELLULAR INFILTRATION ASSESSED BY MONOCLONAL ANTIBODY LABELING IN SEQUENTIAL HUMAN RENAL ALLOGRAFT BIOPSIES. Transplantation, 1986, 42, 352-357.	0.5	126
78	Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines. Annals of Surgical Oncology, 2007, 14, 1924-1933.	0.7	126
79	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology, 2015, 22, 2135-2142.	0.7	126
80	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	5.1	126
81	Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World Journal of Surgery, 1992, 16, 227-233.	0.8	124
82	Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Research, 2008, 18, 405-411.	0.6	124
83	Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients. Annals of Surgical Oncology, 2014, 21, 1075-1081.	0.7	123
84	Prognosis for patients with thin cutaneous melanoma. Cancer, 2003, 98, 1223-1231.	2.0	121
85	Locally advanced melanoma. , 2000, 88, 88-94.		120
86	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	3.2	120
87	Surgical excision margins for primary cutaneous melanoma. The Cochrane Library, 2009, , CD004835.	1.5	119
88	An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Journal of Clinical Oncology, 2007, 25, 8508-8508.	0.8	119
89	Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Annals of Surgical Oncology, 2002, 9, 127-136.	0.7	118
90	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. American Journal of Clinical Pathology, 2004, 122, 532-539.	0.4	117

#	Article	IF	CITATIONS
91	Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research, 2005, 15, 45-51.	0.6	116
92	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). Annals of Surgical Oncology, 2008, 15, 302-309.	0.7	116
93	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 2013, 19, 4589-4598.	3.2	115
94	The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes. Journal of Clinical Oncology, 2005, 23, 4588-4590.	0.8	114
95	Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. Journal of Surgical Oncology, 2011, 104, 379-385.	0.8	112
96	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. Journal of Clinical Oncology, 2010, 28, 4441-4449.	0.8	111
97	Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2001, 8, 766-770.	0.7	109
98	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. Annals of Surgical Oncology, 2005, 12, 429-439.	0.7	109
99	The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology, 2006, 38, 287-301.	0.3	109
100	Prognostic factors in cutaneous desmoplastic melanoma. Cancer, 2010, 116, 4130-4138.	2.0	109
101	Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. Annals of Surgery, 2004, 239, 544-552.	2.1	106
102	Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database. Annals of Surgical Oncology, 2010, 17, 2006-2014.	0.7	106
103	Data Set for Pathology Reporting of Cutaneous Invasive Melanoma. American Journal of Surgical Pathology, 2013, 37, 1797-1814.	2.1	106
104	Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biology and Therapy, 2005, 4, 1318-1324.	1.5	105
105	Noise pollution in the anaesthetic and intensive care environment. Anaesthesia, 1994, 49, 982-986.	1.8	104
106	New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Journal of Surgical Oncology, 2003, 21, 43-52.	1.4	103
107	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	2.1	103
108	Frequency and Duration of Remission After Isolated Limb Perfusion for Melanoma. Archives of Surgery, 1997, 132, 903.	2.3	102

#	Article	IF	CITATIONS
109	Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence. American Journal of Surgical Pathology, 2003, 27, 1197-1202.	2.1	102
110	Pathologic examination of sentinel lymph nodes from melanoma patients. Seminars in Diagnostic Pathology, 2008, 25, 100-111.	1.0	102
111	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000.	0.7	102
112	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	5.8	102
113	Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. , 1997, 19, 589-594.		101
114	Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. Annals of Surgical Oncology, 2007, 14, 1943-1952.	0.7	101
115	Hearing the bad news of a cancer diagnosis: The Australian melanoma patient's perspective. Annals of Oncology, 2001, 12, 365-371.	0.6	100
116	Cutaneous melanoma in the era of molecular profiling. Lancet, The, 2009, 374, 362-365.	6.3	100
117	Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 18-23.	0.7	99
118	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	1.4	96
119	Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. Annals of Surgical Oncology, 2008, 15, 2509-2518.	0.7	95
120	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	2.1	95
121	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 2014, 111, 292-299.	2.9	93
122	A CONTROLLED TRIAL OF CYCLOSPORINE IN RENAL TRANSPLANTATION WITH CONVERSION TO AZATHIOPRINE AND PREDNISOLONE AFTER THREE MONTHS. Transplantation, 1983, 36, 273-276.	0.5	91
123	Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biology and Therapy, 2007, 6, 846-852.	1.5	91
124	Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma. Journal of Clinical Oncology, 2009, 27, 5614-5619.	0.8	91
125	Expression of glucoseâ€regulated stress protein GRP78 is related to progression of melanoma. Histopathology, 2009, 54, 462-470.	1.6	91
126	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3915-3923.	3.2	91

8

#	Article	IF	CITATIONS
127	Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern?. Head and Neck, 2001, 23, 785-790.	0.9	90
128	Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2008, 15, 1476-1484.	0.7	89
129	Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension, 2016, 67, 1263-1272.	1.3	89
130	Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. European Journal of Surgical Oncology, 2009, 35, 313-319.	0.5	87
131	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2015, 2, 671-680.	2.7	86
132	Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma. Annals of Surgery, 2007, 245, 591-596.	2.1	85
133	SOX2 contributes to melanoma cell invasion. Laboratory Investigation, 2012, 92, 362-370.	1.7	85
134	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	0.8	84
135	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. Annals of Surgery, 2012, 255, 357-362.	2.1	83
136	The advantage of using a synoptic pathology report format for cutaneous melanoma. Histopathology, 2008, 52, 130-138.	1.6	82
137	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. Journal of Investigative Dermatology, 2016, 136, 245-254.	0.3	82
138	Title is missing!. , 2017, , .		82
139	A recurrent germline <i><scp>BAP1</scp></i> mutation and extension of the <i><scp>BAP1</scp></i> tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 2015, 88, 267-272.	1.0	81
140	Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 2018, 9, 4627.	5.8	79
141	Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. Journal of Neurosurgery, 2002, 96, 552-558.	0.9	78
142	Follow-up schedules after treatment for malignant melanoma. British Journal of Surgery, 2008, 95, 1401-1407.	0.1	78
143	Intratumoral Molecular Heterogeneity in a <i>BRAF</i> -Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	1.9	78
144	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	2.9	78

#	Article	IF	CITATIONS
145	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. Methods in Molecular Biology, 2014, 1102, 287-324.	0.4	78
146	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 3132-3141.	0.8	78
147	Local and intralesional therapy of inâ€transit melanoma metastases. Journal of Surgical Oncology, 2011, 104, 391-396.	0.8	77
148	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 2019, 30, 815-822.	0.6	77
149	Popliteal lymph node metastasis from primary cutaneous melanoma. European Journal of Surgical Oncology, 2000, 26, 172-176.	0.5	76
150	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
151	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. Cancer, 2009, 115, 5026-5037.	2.0	75
152	Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 2011, 29, 4641-4646.	0.8	75
153	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	3.2	75
154	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 2005, 58, 1163-1169.	1.0	74
155	Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases. Annals of Surgical Oncology, 2015, 22, 1959-1966.	0.7	73
156	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.4	72
157	RAB27A promotes melanoma cell invasion and metastasis <i>via</i> regulation of proâ€invasive exosomes. International Journal of Cancer, 2019, 144, 3070-3085.	2.3	72
158	Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma. Annals of Surgical Oncology, 2004, 11, 829-836.	0.7	71
159	Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. Pathology, 2004, 36, 419-427.	0.3	71
160	Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand. Human Pathology, 2006, 37, 1286-1294.	1.1	71
161	Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncology, The, 2005, 6, 877-885.	5.1	69
162	Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma. American Journal of Surgical Pathology, 2008, 32, 1396-1403.	2.1	69

#	Article	IF	CITATIONS
163	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. Journal of Immunology, 2014, 192, 2505-2513.	0.4	69
164	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8Åmm Separates Higher-Risk and Lower-Risk Tumors. Annals of Surgical Oncology, 2018, 25, 894-902.	0.7	69
165	CYCLOSPORIN CONVERSION VERSUS CONVENTIONAL IMMUNOSUPPRESSION: LONG-TERM FOLLOW-UP AND HISTOLOGICAL EVALUATION. Lancet, The, 1987, 329, 586-591.	6.3	68
166	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	0.7	68
167	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 2010, 23, 45-53.	2.9	68
168	Thin regressing malignant melanoma: Significance of concurrent regional lymph node metastases. Histopathology, 1989, 15, 257-265.	1.6	67
169	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 597-608.	0.7	67
170	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clinical Cancer Research, 2007, 13, 3825-3830.	3.2	67
171	False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. Annals of Surgery, 2008, 247, 1003-1010.	2.1	67
172	Determination of prognosis in metastatic melanoma through integration of clinicoâ€pathologic, mutation, mRNA, microRNA, and protein information. International Journal of Cancer, 2015, 136, 863-874.	2.3	67
173	Soâ€called "malignant blue nevusâ€: Cancer, 2009, 115, 2949-2955.	2.0	66
174	Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	2.1	66
175	Malignant melanoma in childhood: A clinicopathologic study of 13 cases and comparison with spitz nevi. World Journal of Surgery, 1992, 16, 179-185.	0.8	65
176	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	0.6	65
177	Evaluation of Sex-Specific Incidence of Melanoma. JAMA Dermatology, 2020, 156, 553.	2.0	65
178	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. Journal of the National Cancer Institute, 2014, 106, djt435-djt435.	3.0	64
179	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
180	Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. Journal of Surgical Oncology, 2014, 109, 308-313.	0.8	63

#	Article	IF	CITATIONS
181	Targeted alpha therapy for cancer. Physics in Medicine and Biology, 2004, 49, 3703-3712.	1.6	62
182	Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009, 28, 3058-3068.	2.6	62
183	Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer, 2011, 11, 142.	1.1	62
184	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. Annals of Surgery, 2012, 255, 1165-1170.	2.1	62
185	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncolmmunology, 2020, 9, 1659093.	2.1	62
186	A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: The use of monoclonal antibodies and double immunolabeling. Hepatology, 1990, 12, 1305-1313.	3.6	61
187	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. Annals of Surgery, 2009, 249, 473-480.	2.1	61
188	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncolmmunology, 2019, 8, e1537581.	2.1	61
189	Imaging in cutaneous melanoma. Nuclear Medicine Communications, 2008, 29, 847-876.	0.5	60
190	A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 2014, 5, 2912-2917.	0.8	60
191	Defining Lower Limb Lymphedema After Inguinal or Ilio-Inguinal Dissection in Patients With Melanoma Using Classification and Regression Tree Analysis. Annals of Surgery, 2008, 248, 286-293.	2.1	59
192	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 3325-3334.	0.7	59
193	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with <i>BRAF</i> mutation and patient prognosis. Pigment Cell and Melanoma Research, 2015, 28, 254-266.	1.5	59
194	Prognostic Gene Expression Profiling in Cutaneous Melanoma. JAMA Dermatology, 2020, 156, 1004.	2.0	59
195	Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Research, 1997, 7, 500-506.	0.6	57
196	Histopathologic Excision Margin Affects Local Recurrence Rate. Annals of Surgery, 2005, 241, 326-333.	2.1	57
197	Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy. Annals of Surgical Oncology, 2008, 15, 1741-1749.	0.7	56
198	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. Annals of Surgery, 2013, 258, 152-157.	2.1	56

#	Article	IF	CITATIONS
199	Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer, 2009, 115, 1932-1940.	2.0	55
200	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	2.9	55
201	Molecular Genomic Profiling of MelanocyticÂNevi. Journal of Investigative Dermatology, 2019, 139, 1762-1768.	0.3	55
202	Pathology of melanocytic lesions: New, controversial, and clinically important issues. Journal of Surgical Oncology, 2004, 86, 200-211.	0.8	54
203	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	2.3	54
204	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Research, 2009, 19, 94-99.	0.6	53
205	Lymphatic drainage to triangular intermuscular space lymph nodes in melanoma on the back. Journal of Nuclear Medicine, 1996, 37, 964-6.	2.8	53
206	Lymphatic drainage from the skin of the back to retroperitoneal and paravertebral lymph nodes in melanoma patients. Annals of Surgical Oncology, 1998, 5, 384-387.	0.7	52
207	Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients. Annals of Surgical Oncology, 2009, 16, 1184-1192.	0.7	52
208	Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review. Journal of Surgical Oncology, 2014, 109, 348-351.	0.8	52
209	The rationale for sentinel-node biopsy in primary melanoma. Nature Clinical Practice Oncology, 2008, 5, 510-511.	4.3	51
210	Elemental bio-imaging of melanoma in lymph node biopsies. Analyst, The, 2009, 134, 450-453.	1.7	51
211	Lymphatic Drainage From Peri-Umbiiical Skin to Internal Mammary Nodes. Clinical Nuclear Medicine, 1995, 20, 254-255.	0.7	50
212	Asking questions can help: development of a question prompt list for cancer patients seeing a surgeon. European Journal of Cancer Prevention, 2003, 12, 397-405.	0.6	50
213	Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma. Lancet Oncology, The, 2007, 8, 806-812.	5.1	50
214	Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. Journal of Investigative Dermatology, 2012, 132, 2226-2234.	0.3	50
215	Surgical treatment of splenic metastases in patients with melanoma. Journal of the American College of Surgeons, 2003, 197, 38-43.	0.2	49
216	Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as ?Pure? or ?Mixed? May Have Important Prognostic Significance. Annals of Surgical Oncology, 2005, 12, 197-199.	0.7	49

#	Article	IF	CITATIONS
217	Sentinel Node Mapping for Melanoma: Results of Trials and Current Applications. Surgical Oncology Clinics of North America, 2007, 16, 35-54.	0.6	49
218	The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2009, 16, 929-940.	0.7	49
219	Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	1.3	49
220	Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. Journal of Surgical Oncology, 2004, 88, 1-3.	0.8	48
221	Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2008, 15, 2749-2756.	0.7	48
222	The detection and significance of melanoma micrometastases in sentinel nodes. Surgical Oncology, 2008, 17, 165-174.	0.8	48
223	Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australasian Journal of Dermatology, 2009, 50, 266-271.	0.4	48
224	Lymph Node Ratio Provides Prognostic Information in Addition to American Joint Committee on Cancer N Stage in Patients With Melanoma, Even If Quality of Surgery Is Standardized. Annals of Surgery, 2011, 253, 109-115.	2.1	48
225	Melanomas of unknown primary have a mutation profile consistent with cutaneous sunâ€exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	1.5	48
226	Epitrochlear lymph nodes as a site of melanoma metastasis. Annals of Surgical Oncology, 1998, 5, 248-252.	0.7	47
227	Increased expression of apoptotic markers in melanoma. Melanoma Research, 2003, 13, 137-145.	0.6	47
228	Spitz naevus: diagnostic problems and their management implications. Pathology, 2004, 36, 452-457.	0.3	47
229	The Complex Relationships Between Sentinel Node Positivity, Patient Age, and Primary Tumor Desmoplasia: Analysis of 2303 Melanoma Patients Treated at a Single Center. Annals of Surgical Oncology, 2008, 15, 630-637.	0.7	47
230	Histologically Ambiguous ("Borderlineâ€) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. Archives of Pathology and Laboratory Medicine, 2010, 134, 1770-1777.	1.2	47
231	Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for hemodialysis access. American Journal of Surgery, 1997, 173, 280-283.	0.9	46
232	Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Review of Anticancer Therapy, 2006, 6, 671-678.	1.1	46
233	Quality Assurance Parameters and Predictors of Outcome for Ilioinguinal and Inguinal Dissection in a Contemporary Melanoma Patient Population. Annals of Surgical Oncology, 2011, 18, 2521-2528.	0.7	46
234	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Modern Pathology, 2014, 27, 936-944.	2.9	46

#	Article	IF	CITATIONS
235	Should Tumor Mitotic Rate and Patient Age, As Well As Tumor Thickness, be Used to Select Melanoma Patients for Sentinel Node Biopsy?. Annals of Surgical Oncology, 2004, 11, 233-235.	0.7	45
236	Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. European Journal of Surgical Oncology, 2004, 30, 1107-1112.	0.5	45
237	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. Annals of Surgery, 2009, 249, 641-647.	2.1	45
238	Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage III Melanoma. Annals of Surgery, 2012, 255, 771-776.	2.1	45
239	Sentinel Lymph Nodes Containing Very Small (<0.1Âmm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. Annals of Surgical Oncology, 2012, 19, 1089-1099.	0.7	45
240	The History of Sentinel Lymph Node Biopsy. Cancer Journal (Sudbury, Mass), 2015, 21, 3-6.	1.0	45
241	Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. Melanoma Research, 2005, 15, 531-537.	0.6	44
242	Extended experience and modifications in the design and concepts of the keystone design island flap. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 1359-1363.	0.5	44
243	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
244	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Annals of Surgical Oncology, 2016, 23, 1096-1103.	0.7	43
245	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	2.9	43
246	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case–Control Study. Annals of Surgical Oncology, 2016, 23, 1082-1089.	0.7	43
247	Clinical Features Associated With Individuals at Higher Risk of Melanoma. JAMA Dermatology, 2017, 153, 23.	2.0	43
248	Sentinel Node Biopsy for Melanoma: Where Have We Been and Where Are We Going?. Annals of Surgical Oncology, 2004, 11, 147S-151S.	0.7	43
249	Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. Journal of the American College of Surgeons, 1995, 180, 402-9.	0.2	43
250	Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role. Annals of Surgical Oncology, 2001, 8, 564-565.	0.7	42
251	Threeâ€dimensional visualization of skin lymphatic drainage patterns of the head and neck. Head and Neck, 2009, 31, 1316-1325.	0.9	42
252	Isolated limb infusion: A review. Journal of Surgical Oncology, 2009, 100, 169-177.	0.8	42

#	Article	IF	CITATIONS
253	The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients. Annals of Surgical Oncology, 2009, 16, 571-577.	0.7	42
254	Surgeons' Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey. Annals of Surgical Oncology, 2012, 19, 4322-4329.	0.7	42
255	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 2012, 61, 889-898.	1.6	42
256	Margins of excision and prognostic factors for cutaneous eyelid melanomas. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 1066-1073.	0.5	42
257	Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer, 1998, 83, 1128-35.	2.0	42
258	Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology, 2007, 39, 551-557.	0.3	41
259	Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 2009, 62, 915-919.	1.0	41
260	Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology, 2010, 56, 768-774.	1.6	41
261	Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. Journal of the American Academy of Dermatology, 2007, 56, 869-871.	0.6	40
262	Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors. International Journal of Surgical Pathology, 2009, 17, 361-367.	0.4	40
263	Clinicopathologic features associated with efficacy and longâ€ŧerm survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	2.0	40
264	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	1.7	40
265	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. Journal of Clinical Oncology, 2017, 35, 1721-1729.	0.8	40
266	Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. British Journal of Cancer, 2001, 85, 157-165.	2.9	39
267	The Reproducibility in Routine Clinical Practice of Sentinel Lymph Node Identification by Pre-operative Lymphoscintigraphy in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2007, 14, 899-905.	0.7	39
268	p16INK4a Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors. Neoplasia, 2008, 10, 1231-1239.	2.3	39
269	Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 2012, 24, e131-e136.	0.6	39
270	Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. Annals of Surgical Oncology, 2012, 19, 1774-1781.	0.7	39

#	Article	IF	CITATIONS
271	Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. Journal of Surgical Oncology, 2013, 108, 129-135.	0.8	39
272	Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm). Histopathology, 1998, 33, 406-413.	1.6	38
273	Interleukin-10 regulates arterial pressure in early primate pregnancy. Cytokine, 2005, 29, 176-185.	1.4	38
274	Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. Journal of Surgical Oncology, 2011, 104, 397-404.	0.8	37
275	Effects of <scp>BRAF</scp> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell and Melanoma Research, 2013, 26, 499-508.	1.5	37
276	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 2015, 28, 884-894.	2.9	37
277	Active surveillance of patients who have sentinel node positive melanoma: An international, multiâ€institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLTâ€2). Cancer, 2021, 127, 2251-2261.	2.0	37
278	PRIMARY MUCOSAL AND GLANS PENIS MELANOMAS: THE SYDNEY MELANOMA UNIT EXPERIENCE. Australian and New Zealand Journal of Surgery, 1999, 69, 121-126.	0.2	36
279	Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients?. Annals of Surgical Oncology, 2008, 15, 3022-3027.	0.7	36
280	The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 3301-3303.	0.7	36
281	Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer, 2014, 14, 780.	1.1	36
282	Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. Annals of Surgery, 2014, 260, 149-157.	2.1	36
283	EDITORIAL — What is a «sentinel» lymph node?. European Journal of Surgical Oncology, 2000, 26, 103-104.	0.5	35
284	Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. European Journal of Surgical Oncology, 2004, 30, 433-439.	0.5	35
285	Patients' perspectives of long-term follow-up for localised cutaneous melanoma. European Journal of Surgical Oncology, 2013, 39, 297-303.	0.5	35
286	Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. Annals of Surgical Oncology, 2014, 21, 2245-2251.	0.7	35
287	Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. Annals of Surgical Oncology, 2014, 21, 3985-3991.	0.7	35
288	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 2018, 25, 2541-2549.	0.7	35

JOHN F THOMPSON

#	Article	IF	CITATIONS
289	Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. Annals of Surgical Oncology, 2019, 26, 2486-2494.	0.7	35
290	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute, 2019, 111, 1314-1322.	3.0	35
291	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. Journal of Pathology: Clinical Research, 2020, 6, 195-206.	1.3	35
292	Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. Pathology, 2004, 36, 496-503.	0.3	34
293	Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. Annals of Surgical Oncology, 2010, 17, 1995-2005.	0.7	34
294	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery, 2011, 253, 1155-1164.	2.1	34
295	Role of Lymphoscintigraphy for Selective Sentinel Lymphadenectomy. Cancer Treatment and Research, 2005, 127, 15-38.	0.2	33
296	Functional anatomy of the lymphatics draining the skin: a detailed statistical analysis. Journal of Anatomy, 2010, 216, 344-355.	0.9	33
297	Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell and Melanoma Research, 2013, 26, 326-337.	1.5	33
298	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. Annals of Surgical Oncology, 2014, 21, 3108-3116.	0.7	33
299	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Modern Pathology, 2017, 30, 1538-1550.	2.9	33
300	Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137.	5.8	33
301	SKIN CANCER IN RENAL TRANSPLANT PATIENTS TREATED WITH CYCLOSPORIN. Lancet, The, 1985, 325, 158-159.	6.3	32
302	Patients' attitudes to xenotransplantation. Lancet, The, 1997, 349, 1031.	6.3	32
303	Intraoperative Frozen-Section Evaluation Can Reduce Accuracy of Pathologic Assessment of Sentinel Nodes in Melanoma Patients. Journal of the American College of Surgeons, 2005, 201, 821-823.	0.2	32
304	Updated evidenceâ€based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Medical Journal of Australia, 2018, 208, 137-142.	0.8	32
305	GOUT AND HYPERURICAEMIA IN PATIENTS ON CYCLOSPORIN AND DIURETICS. Lancet, The, 1985, 325, 453.	6.3	31
306	Nuclear medicine aspects of melanoma and breast lymphatic mapping. Seminars in Oncology, 2004, 31, 338-348.	0.8	31

18

#	Article	IF	CITATIONS
307	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1–2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology, 2016, 23, 1071-1081.	0.7	31
308	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. Annals of Surgical Oncology, 2017, 24, 2080-2088.	0.7	31
309	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	0.8	31
310	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	0.8	31
311	Aortic Occlusion and Vascular Isolation Allowing Avascular Hepatic Resection. Archives of Surgery, 1990, 125, 1482.	2.3	30
312	Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. Annals of Surgical Oncology, 2010, 17, 3015-3020.	0.7	30
313	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	0.7	30
314	BAP1 expression in cutaneous melanoma: a pilot study. Pathology, 2013, 45, 606-609.	0.3	30
315	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	5.7	30
316	Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Research, 2001, 11, 423-431.	0.6	29
317	Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. European Journal of Surgical Oncology, 2006, 32, 780-784.	0.5	29
318	Detection of second primary cutaneous melanomas. European Journal of Surgical Oncology, 2008, 34, 587-592.	0.5	29
319	Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution. Annals of Surgical Oncology, 2011, 18, 1877-1883.	0.7	29
320	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer, 2012, 118, 4519-4529.	2.0	29
321	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	1.6	29
322	Followâ€up of early stage melanoma: Specialist clinician perspectives on the functions of followâ€up and implications for extending followâ€up intervals. Journal of Surgical Oncology, 2013, 107, 463-468.	0.8	29
323	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2019, 26, 1860-1868.	0.7	29
324	The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Annals of Surgical Oncology, 2001, 8, 44S-47S.	0.7	29

#	Article	IF	CITATIONS
325	Demonstration of second-tier lymph nodes during preoperative lymphoscintigraphy for melanoma: Incidence varies with primary tumor site. Annals of Surgical Oncology, 1998, 5, 517-521.	0.7	28
326	The Role of Lymphoscintigraphy in the Detection of Lymph Node Drainage in Melanoma. Surgical Oncology Clinics of North America, 2006, 15, 285-300.	0.6	28
327	The utility of ultrasound in patients with melanoma. Expert Review of Anticancer Therapy, 2007, 7, 1633-1642.	1.1	28
328	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. Annals of Surgical Oncology, 2008, 15, 323-332.	0.7	28
329	Sentinel Node Status Prediction by Four Statistical Models. Annals of Surgery, 2009, 250, 964-969.	2.1	28
330	The important role of radiation treatment in the management of Merkel cell carcinoma. British Journal of Dermatology, 2013, 169, 975-982.	1.4	28
331	Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. Annals of Surgical Oncology, 2014, 21, 292-299.	0.7	28
332	Subungual Melanoma of the Hand. Annals of Surgical Oncology, 2019, 26, 1035-1043.	0.7	28
333	A risk prediction model for the development of subsequent primary melanoma in a populationâ€based cohort. British Journal of Dermatology, 2020, 182, 1148-1157.	1.4	28
334	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	0.8	28
335	Intramedullary spinal cord metastasis from carcinoma of the lung: detection by positron emission tomography. European Journal of Cancer, 1997, 33, 508-509.	1.3	27
336	Saturable dose–response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Research, 2001, 11, 611-618.	0.6	27
337	Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. Melanoma Research, 2003, 13, 259-261.	0.6	27
338	Argyrophilic Staining of Nucleolar Organizer Region Count and Morphometry in Benign and Malignant Melanocytic Lesions. American Journal of Dermatopathology, 2003, 25, 190-197.	0.3	27
339	Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. Journal of Investigative Dermatology, 2009, 129, 1972-1982.	0.3	27
340	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naÃ ⁻ ve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 2019, 25, 3247-3258.	3.2	27
341	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	1.7	27
342	Acute and subacute fulminant hepatic failure: the role of liver transplantation. Medical Journal of Australia, 1991, 154, 724-728.	0.8	27

#	Article	IF	CITATIONS
343	Variability of cutaneous lymphatic flow rates in melanoma patients. Melanoma Research, 1998, 8, 279-282.	0.6	26
344	Surgical Management of Primary Cutaneous Melanoma: Excision Margins and the Role of Sentinel Lymph Node Examination. Surgical Oncology Clinics of North America, 2006, 15, 301-318.	0.6	26
345	Lymph node ratio in melanoma. Cancer, 2009, 115, 2384-2387.	2.0	26
346	Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma. Annals of Surgery, 2009, 249, 1008-1013.	2.1	26
347	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.3	26
348	Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. Medical Journal of Australia, 2019, 210, 41-47.	0.8	26
349	Variation in cutaneous lymphatic flow rates. Annals of Surgical Oncology, 1997, 4, 279-280.	0.7	25
350	In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. European Journal of Radiology, 2005, 53, 506-513.	1.2	25
351	Guidelines for lymphoscintigraphy and F18 FDG PET scans in Melanoma. Journal of Surgical Oncology, 2011, 104, 405-419.	0.8	25
352	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 2019, 51, 39-45.	0.3	25
353	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	0.6	25
354	Direct Lymphatic Drainage From the Skin of the Forearm to a Supraclavicular Node. Clinical Nuclear Medicine, 1996, 21, 387-389.	0.7	25
355	Latex allergy: an emerging clinical and occupational health problem. Anaesthesia, 1997, 52, 570-575.	1.8	24
356	Sentinel node biopsy. , 1997, 66, 270-272.		24
357	High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Journal of Medical Imaging and Radiation Oncology, 1999, 43, 148-152.	0.6	24
358	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. American Journal of Clinical Pathology, 2008, 130, 715-723.	0.4	24
359	Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2011, 18, 3292-3299.	0.7	24
360	Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Research, 1996, 6, 267-271.	0.6	23

#	Article	IF	CITATIONS
361	Cutaneous melanoma in childhood: Incidence and prognosis. Australasian Journal of Dermatology, 1997, 38, S44-S48.	0.4	23
362	Contralateral groin node metastasis from lower limb melanoma. European Journal of Cancer, 1997, 33, 976-977.	1.3	23
363	CADAVERIC LIVER PROCUREMENT USING AORTIC PERFUSION ONLY. ANZ Journal of Surgery, 1998, 68, 275-277.	0.3	23
364	Lymph-node metastases in patients with melanoma: what is the optimum management?. Lancet Oncology, The, 2001, 2, 614-621.	5.1	23
365	Authors' Response to a Letter to the Editor Re: Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery, 2007, 245, 828-829.	2.1	23
366	Isolated limb infusion: Technical aspects. Journal of Surgical Oncology, 2014, 109, 352-356.	0.8	23
367	Imaging Sentinel Lymph Nodes. Cancer Journal (Sudbury, Mass), 2015, 21, 25-32.	1.0	23
368	Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. Dermatology, 2020, 236, 111-116.	0.9	23
369	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	0.8	23
370	Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. American Journal of Clinical Pathology, 2004, 122, 532-9.	0.4	23
371	Role of T-Cell-Subset Monitoring in Renal-Allograft Recipients. New England Journal of Medicine, 1982, 306, 1110-1111.	13.9	22
372	Lymphatic mapping and selective lymphadenectomy for melanoma: not yet standard therapy. European Journal of Surgical Oncology, 1997, 23, 397-398.	0.5	22
373	The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. Journal of Cutaneous Pathology, 2006, 33, 395-396.	0.7	22
374	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. European Journal of Surgical Oncology, 2013, 39, 179-184.	0.5	22
375	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2017, 24, 2089-2094.	0.7	22
376	Exclusive Lymphatic Drainage from a Melanoma on the Back to Intraabdominal Lymph Nodes. Clinical Nuclear Medicine, 1998, 23, 71-73.	0.7	22
377	Hypertrichosis and Multiple Cutaneous Squamous Cell Carcinomas in Association with Cyclosporin a Therapy. Journal of the Royal Society of Medicine, 1983, 76, 786-787.	1.1	21
378	Teaching points on lymphatic mapping for melanoma from the sydney melanoma unit. Seminars in Oncology, 2004, 31, 349-356.	0.8	21

#	Article	IF	CITATIONS
379	Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Research, 2004, 14, 263-268.	0.6	21
380	Music in the operating theatre. British Journal of Surgery, 2005, 82, 1586-1587.	0.1	21
381	Isolated Limb Infusion as Palliative Treatment for Advanced Limb Disease in Patients with AJCC Stage IV Melanoma. Annals of Surgical Oncology, 2009, 16, 1193-1201.	0.7	21
382	Reconstruction after wide excision of primary cutaneous melanomas: part l—the head and neck. Lancet Oncology, The, 2009, 10, 700-708.	5.1	21
383	Sentinel Lymph Node Biopsy for Melanoma: Critical Assessment at its Twentieth Anniversary. Surgical Oncology Clinics of North America, 2011, 20, 57-78.	0.6	21
384	Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study. Gastrointestinal Endoscopy, 2011, 73, 750-756.	0.5	21
385	Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management. British Journal of Dermatology, 2015, 172, 571-573.	1.4	21
386	Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. Journal of the American College of Surgeons, 2017, 224, 635-642.	0.2	21
387	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	5.8	21
388	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 2019, 26, 25-32.	0.7	21
389	The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Populationâ€based data on diagnosis and management. Australasian Journal of Dermatology, 2019, 60, 118-125.	0.4	21
390	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
391	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 2021, 157, 166.	2.0	21
392	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
393	Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision. Cancer, 2004, 101, 2141-2142.	2.0	20
394	Melanoma Metastases in Regional Lymph Nodes Are Accurately Detected by Proton Magnetic Resonance Spectroscopy of Fine-Needle Aspirate Biopsy Samples. Annals of Surgical Oncology, 2005, 12, 943-949.	0.7	20
395	Treatment of Refractory Chromomycosis by Isolated Limb Infusion with Melphalan and Actinomycin D. Journal of Cutaneous Medicine and Surgery, 2006, 10, 48-51.	0.6	20
396	Survival in Patients With Desmoplastic Melanoma. Journal of Clinical Oncology, 2006, 24, e12-e12.	0.8	20

#	Article	IF	CITATIONS
397	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. Future Oncology, 2008, 4, 535-551.	1.1	20
398	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncology, The, 2010, 11, 391-400.	5.1	20
399	Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. Annals of Surgical Oncology, 2013, 20, 3969-3975.	0.7	20
400	A novel hypoxia-associated subset of FN1highMITFlow melanoma cells: identification, characterization, and prognostic value. Modern Pathology, 2014, 27, 1088-1100.	2.9	20
401	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 2014, 32, 816-823.	0.8	20
402	Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor. Annals of Surgical Oncology, 2015, 22, 1598-1603.	0.7	20
403	Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. Journal of the American College of Surgeons, 2017, 225, 302-311.	0.2	20
404	Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Research, 2018, 28, 134-142.	0.6	20
405	Embolisation of host kidneys for the control of hypertension after renal transplantation: radiological aspects. British Journal of Radiology, 1984, 57, 279-284.	1.0	19
406	Sentinel Node Metastasis From Thin Melanomas With Vertical Growth Phase. Annals of Surgical Oncology, 2000, 7, 251-252.	0.7	19
407	Sentinel node biopsy for melanoma: Where have we been and where are we going?. Annals of Surgical Oncology, 2004, 11, 147S-151S.	0.7	19
408	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology, 2011, 58, 886-895.	1.6	19
409	Isolated Limb Perfusion and Isolated Limb Infusion for Malignant Lesions of the Extremities. Current Problems in Surgery, 2011, 48, 371-430.	0.6	19
410	Is Melphalan Dose Adjustment According to Ideal Body Weight Useful in Isolated Limb Infusion for Melanoma?. Annals of Surgical Oncology, 2012, 19, 3050-3056.	0.7	19
411	Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. BMC Health Services Research, 2012, 12, 468.	0.9	19
412	Local and regional therapies for melanoma: Many arrows in the quiver. Journal of Surgical Oncology, 2014, 109, 295-295.	0.8	19
413	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.3	19
414	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. European Journal of Surgical Oncology, 2015, 41, 830-836.	0.5	19

#	Article	IF	CITATIONS
415	The first five years' clinical experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1992, 156, 9-16.	0.8	18
416	Sentinel lymph node biopsy in patients with melanoma and breast cancer. Internal Medicine Journal, 2001, 31, 547-553.	0.5	18
417	CASE REPORT Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. Australasian Journal of Dermatology, 2001, 42, 106-109.	0.4	18
418	Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. Analyst, The, 2003, 128, 217-219.	1.7	18
419	The history and future of melanoma staging. Journal of Surgical Oncology, 2004, 86, 224-235.	0.8	18
420	Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology, 2004, 36, 561-565.	0.3	18
421	BENEFITS OF SENTINEL NODE BIOPSY FOR MELANOMA: A REVIEW BASED ON INTERIM RESULTS OF THE FIRST MULTICENTER SELECTIVE LYMPHADENECTOMY TRIAL. ANZ Journal of Surgery, 2006, 76, 100-103.	0.3	18
422	Is Sentinel Lymph Node Biopsy Appropriate in Patients With Thin Melanomas: Too Early To Tell?. Annals of Surgical Oncology, 2006, 13, 279-281.	0.7	18
423	Ultrasound assessment of lymph nodes in the management of earlyâ€stage melanoma. Journal of Surgical Oncology, 2011, 104, 354-360.	0.8	18
424	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	2.9	18
425	Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia. Annals of Surgical Oncology, 2018, 25, 617-625.	0.7	18
426	Antimony concentrations in nodal tissue can confirm sentinel node identity. Modern Pathology, 2004, 17, 1191-1197.	2.9	17
427	Selective Sentinel Lymphadenectomy: Progress to Date and Prospects for the Future. Cancer Treatment and Research, 2005, 127, 269-287.	0.2	17
428	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808.	0.6	17
429	The Management of Cervical Lymph Nodes in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 3926-3932.	0.7	17
430	What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Research, 2013, 23, 167-174.	0.6	17
431	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 2016, 23, 2658-2663.	0.7	17
432	Initial report of the Australian National Pilot Liver Transplantation Programme. Medical Journal of Australia, 1987, 147, 372-380.	0.8	16

JOHN F THOMPSON

#	Article	IF	CITATIONS
433	Non-Subungual Melanomas of the Hand. Journal of Hand Surgery, 1992, 17, 433-436.	0.9	16
434	Obtaining Consent for Organ Donation in Nine NSW Metropolitan Hospitals. Anaesthesia and Intensive Care, 1995, 23, 81-87.	0.2	16
435	Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions. Melanoma Research, 2003, 13, 581-586.	0.6	16
436	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. Journal of the American Academy of Dermatology, 2007, 56, 889-890.	0.6	16
437	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell and Melanoma Research, 2014, 27, 1106-1116.	1.5	16
438	BAP1-inactivated Spitzoid Naevi. American Journal of Surgical Pathology, 2015, 39, 722.	2.1	16
439	Cross-cultural development of a quality-of-life measure for patients with melanoma. Melanoma Research, 2015, 25, 47-58.	0.6	16
440	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 2017, 24, 3245-3251.	0.7	16
441	Inter―and intrapatient heterogeneity of indoleamine 2,3â€dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	1.6	16
442	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer, 2021, 142, 10-17.	1.3	16
443	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. Annals of Surgery, 2021, 273, 814-820.	2.1	16
444	Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021, 34, 1999-2008.	2.9	16
445	Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Research, 1994, 4 Suppl 1, 45-50.	0.6	16
446	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
447	CONTROL OF HYPERTENSION AFTER RENAL TRANSPLANTATION BY EMBOLISATION OF HOST KIDNEYS. Lancet, The, 1984, 324, 424-427.	6.3	15
448	COMMON BILE DUCT OBSTRUCTION DUE TO INTRALUMINAL METASTATIC MELANOMA. ANZ Journal of Surgery, 1993, 63, 502-504.	0.3	15
449	Isolated limb perfusion with urokinase for acute ischemia. Journal of Vascular Surgery, 1993, 17, 408-413.	0.6	15
450	Melanoma of the nose. British Journal of Surgery, 2005, 84, 986-989.	0.1	15

#	Article	IF	CITATIONS
451	Major Amputation for Irresectable Extremity Melanoma After Failure of Isolated Limb Infusion. Annals of Surgical Oncology, 2009, 16, 1543-1547.	0.7	15
452	Peritoneal melanosis associated with metastatic melanoma involving the omentum. Pathology, 2012, 44, 255-257.	0.3	15
453	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology, 2013, 45, 55-61.	0.3	15
454	Cardiac Metastasis in Merkel Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, e52-e53.	0.8	15
455	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 2015, 8, 192.	0.6	15
456	Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Research, 2017, 27, 457-462.	0.6	15
457	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e320-e325.	1.8	15
458	The Identification of Potential Cadaveric Organ Donors. Anaesthesia and Intensive Care, 1995, 23, 75-80.	0.2	14
459	Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Surgery, 1996, 119, 112-114.	1.0	14
460	The Unpredictability of Lymphatic Drainage from the Ear in Melanoma Patients, and Its Implications for Management. Annals of Surgical Oncology, 2013, 20, 1707-1713.	0.7	14
461	The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma. Annals of Surgical Oncology, 2015, 22, 4067-4072.	0.7	14
462	Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer, 2016, 16, 372.	1.1	14
463	Melanoma patient imaging in the era of effective systemic therapies. European Journal of Surgical Oncology, 2017, 43, 1517-1527.	0.5	14
464	Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience. Annals of Surgical Oncology, 2018, 25, 2178-2183.	0.7	14
465	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	1.3	14
466	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	1.7	14
467	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 2020, 126, 4717-4725.	2.0	14
468	Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Research, 2020, 30, 358-363.	0.6	14

JOHN F THOMPSON

#	Article	IF	CITATIONS
469	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1290-1298.	1.3	14
470	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.4	14
471	DELAYED RUPTURE OF THE SPLEEN 5 1/2 YEARS AFTER CONSERVATIVE MANAGEMENT OF TRAUMATIC SPLENIC INJURY. ANZ Journal of Surgery, 1996, 66, 494-495.	0.3	13
472	MELANOMA OF THE LIP. ANZ Journal of Surgery, 1996, 66, 327-330.	0.3	13
473	Melanoma Metastases in Triangular Intermuscular Space Lymph Nodes. Annals of Surgical Oncology, 1999, 6, 811-811.	0.7	13
474	Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Annals of Surgical Oncology, 2004, 11, 174S-178S.	0.7	13
475	Current status of isolated limb infusion with mild hyperthermia for melanoma. International Journal of Hyperthermia, 2008, 24, 219-225.	1.1	13
476	Lymphoma occurring in patients with cutaneous melanoma. Journal of Clinical Pathology, 2010, 63, 777-781.	1.0	13
477	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. Pathology, 2010, 42, 287-289.	0.3	13
478	Free flap reconstruction for melanoma of the head and neck: indications and outcomes. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 205-212.	0.5	13
479	The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1999-2004.	3.3	13
480	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329.	0.7	13
481	Radiofrequency ablation in metastatic melanoma. Journal of Surgical Oncology, 2014, 109, 366-369.	0.8	13
482	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	0.7	13
483	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. Journal of Surgical Oncology, 2018, 118, 599-605.	0.8	13
484	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	1.6	13
485	The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 2020, 33, 1369-1379.	2.9	13
486	A multicentre study of naevusâ€associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.4	13

#	Article	IF	CITATIONS
487	MONOCLONAL ANTIBODIES AND FINE NEEDLE ASPIRATION CYTOLOGY IN DETECTING RENAL ALLOGRAFT REJECTION. Lancet, The, 1982, 320, 278.	6.3	12
488	THE MANAGEMENT OF PANCREATIC CARCINOMA: A REVIEW OF 173 CASES. ANZ Journal of Surgery, 1983, 53, 25-30.	0.3	12
489	Surgical resection of pulmonary metastatic melanoma: A review of 83 thoracotomies. Heart, Lung and Circulation, 1996, 5, 111-114.	0.1	12
490	The Sydney Melanoma Unit—a multidisciplinary melanoma treatment center. Surgical Clinics of North America, 2003, 83, 431-451.	0.5	12
491	An Integrated Tree-Based Classification Approach to Prognostic Grouping with Application to Localized Melanoma Patients. Journal of Biopharmaceutical Statistics, 2007, 17, 445-460.	0.4	12
492	Re-evaluation of a Scoring System to Predict Nonsentinel-Node Metastasis and Prognosis in Melanoma Patients. Journal of the American College of Surgeons, 2010, 211, 522-525.	0.2	12
493	The FACT-Melanoma Quality-of-Life Instrument. Melanoma Research, 2013, 23, 61-69.	0.6	12
494	Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible. BMC Research Notes, 2014, 7, 412.	0.6	12
495	The Role of Sentinel Lymph Node Biopsy in Patients with Merkel Cell Carcinoma: Uncertainty Prevails. Annals of Surgical Oncology, 2014, 21, 1517-1519.	0.7	12
496	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2–4 mm in Thickness). Annals of Surgery, 2014, 260, 1095-1102.	2.1	12
497	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the â€~Australian guidelines for the management of cutaneous melanoma'. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.4	12
498	Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A populationâ€based study in New South Wales, Australia. Australasian Journal of Dermatology, 2017, 58, 278-285.	0.4	12
499	Current management of patients with melanoma who are found to be sentinel nodeâ€positive. ANZ Journal of Surgery, 2020, 90, 491-496.	0.3	12
500	Do we need to rethink the diagnoses melanoma <i>in situ</i> and severely dysplastic naevus?. British Journal of Dermatology, 2022, 186, 1030-1032.	1.4	12
501	CONTROL OF LIFE-THREATENING BLEEDING FROM CAPUT MEDUSAE BY UMBILICAL VEIN EMBOLISATION. Lancet, The, 1989, 333, 736.	6.3	11
502	Hemodynamics of conscious unrestrained baboons, including cardiac output. Journal of Applied Physiology, 1990, 68, 2373-2379.	1.2	11
503	TREATMENT OF LARGE, PERSISTENT LYMPHOCOELES USING AN ARGON BEAM COAGULATOR AND TALC. ANZ Journal of Surgery, 1998, 68, 743-744.	0.3	11
504	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. American Journal of Surgical Pathology, 2008, 32, 1106-1107.	2.1	11

#	Article	IF	CITATIONS
505	Sentinel-Node Biopsy in Melanoma. New England Journal of Medicine, 2014, 370, 2148-2150.	13.9	11
506	How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?. Annals of Surgical Oncology, 2015, 22, 1164-1171.	0.7	11
507	Cermline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. Pathology, 2017, 49, 539-542.	0.3	11
508	Outcome of Melanoma Patients Who Did Not Proceed to Sentinel Node Biopsy After Preoperative Lymphoscintigraphy. Annals of Surgical Oncology, 2017, 24, 117-126.	0.7	11
509	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. American Journal of Surgical Pathology, 2018, 42, 359-366.	2.1	11
510	ASO Author Reflections: Limited Surgery Plus Radiotherapy for Melanoma Patients with Cervical Node Metastases. Annals of Surgical Oncology, 2018, 25, 912-913.	0.7	11
511	Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients. Annals of Surgical Oncology, 2019, 26, 2855-2863.	0.7	11
512	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Review of Clinical Pharmacology, 2019, 12, 1107-1119.	1.3	11
513	GPs' involvement in diagnosing, treating, and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study. BJGP Open, 2020, 4, bjgpopen20X101028.	0.9	11
514	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). Journal of Clinical Oncology, 2009, 27, LBA9084-LBA9084.	0.8	11
515	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1607-1616.	0.3	11
516	Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy. Journal of Surgical Oncology, 1983, 23, 223-227.	0.8	10
517	SURGICAL ONCOLOGY AND THE ROLE OF REGIONAL CHEMOTHERAPY. ANZ Journal of Surgery, 1992, 62, 691-696.	0.3	10
518	EFFECTS OF TOTAL HEPATECTOMY: STUDIES IN A PORCINE MODEL. ANZ Journal of Surgery, 1994, 64, 560-564.	0.3	10
519	Can Cadaveric Organ Donation Rates be Improved?. Anaesthesia and Intensive Care, 1995, 23, 99-103.	0.2	10
520	Pharmacokinetics of Regional Therapy: Isolated Limb Infusion and Other Low Flow Techniques for Extremity Melanoma. Surgical Oncology Clinics of North America, 2008, 17, 795-804.	0.6	10
521	Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases. Dermatology, 2008, 216, 361-362.	0.9	10
522	Sentinel Node Biopsy: Facts to Clear the Alleged Clouds—Reply. Archives of Dermatology, 2008, 144, 687.	1.7	10

#	Article	IF	CITATIONS
523	Biospecimen banking: The pathway to personalized medicine for patients with cancer. Journal of Surgical Oncology, 2013, 107, 681-682.	0.8	10
524	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 910-919.	0.6	10
525	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. American Journal of Surgical Pathology, 2020, 44, 357-367.	2.1	10
526	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	0.7	10
527	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. Trials, 2021, 22, 324.	0.7	10
528	Direct Lymphatic Drainage From a Melanoma on the Back to Paravertebral Lymph Nodes in the Thorax. Clinical Nuclear Medicine, 1999, 24, 388-389.	0.7	10
529	RIGHT CHYLOTHORAX FOLLOWING LEFT RADICAL NECK DISSECTION. ANZ Journal of Surgery, 1993, 63, 77-79.	0.3	9
530	Primary Melanoma of the Lung. , 2006, , 293-297.		9
531	Mapping Melanoma Lymphoscintigraphy Data onto a 3D Anatomically Based Model. Annals of Biomedical Engineering, 2007, 35, 1444-1457.	1.3	9
532	Cytological features of melanoma in exfoliative fluid specimens. Journal of Clinical Pathology, 2009, 62, 638-643.	1.0	9
533	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	0.7	9
534	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.3	9
535	Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications. Annals of Surgical Oncology, 2017, 24, 2071-2079.	0.7	9
536	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. British Journal of Cancer, 2018, 119, 713-723.	2.9	9
537	Response to Comment on "Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does Not Provide Reliable Staging. Annals of Surgery, 2019, Publish Ahead of Print, e104-e105.	2.1	9
538	Multiplex melanoma families are enriched for polygenic risk. Human Molecular Genetics, 2020, 29, 2976-2985.	1.4	9
539	Treatment of primary Merkel cell carcinoma: Radiotherapy can be an effective, less morbid alternative to surgery. European Journal of Surgical Oncology, 2021, 47, 483-485.	0.5	9
540	Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. Advances in Therapy, 2021, 38, 3506-3530.	1.3	9

#	Article	IF	CITATIONS
541	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). Journal of Clinical Oncology, 2009, 27, LBA9084-LBA9084.	0.8	9
542	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma Journal of Clinical Oncology, 2016, 34, 9583-9583.	0.8	9
543	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian Journal of General Practice, 2019, 48, 357-362.	0.3	9
544	IS PREGRAFT BLOOD TRANSFUSION BENEFICIAL IN CYCLOSPORIN-TREATED RENAL TRANSPLANT RECIPIENTS?. Lancet, The, 1984, 323, 98.	6.3	8
545	New route for metastatic spread of melanoma?. Lancet, The, 1993, 341, 302.	6.3	8
546	Evidence for Preeclampsia in a Baboon Pregnancy with Twins. Hypertension in Pregnancy, 1997, 16, 223-228.	0.5	8
547	Correspondence. European Journal of Cancer, 1998, 34, 203-204.	1.3	8
548	Lymphatic mapping and sentinel node biopsy for melanoma. Expert Review of Anticancer Therapy, 2001, 1, 446-452.	1.1	8
549	Minimally Invasive Radio-Guided Surgery for Recurrent Thyroid Cancer Using Iodine-123. Clinical Nuclear Medicine, 2005, 30, 43-44.	0.7	8
550	Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. European Journal of Surgical Oncology, 2005, 31, 323-324.	0.5	8
551	Metastatic Occlusion of a Lymphatic Collecting Vessel in a Patient With Cutaneous Melanoma and Clinically Normal Lymph Nodes. Clinical Nuclear Medicine, 2007, 32, 312-313.	0.7	8
552	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma–Mass Spectrometry. Annals of Surgical Oncology, 2008, 15, 934-940.	0.7	8
553	The Value of Sentinel Node Biopsy in Patients with Primary Cutaneous Melanoma. Dermatologic Surgery, 2008, 34, 550-555.	0.4	8
554	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Research, 2010, 20, 203-211.	0.6	8
555	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. British Journal of Dermatology, 2012, 166, 1319-1326.	1.4	8
556	Isolated Limb Infusion and Isolated Limb Perfusion for Melanoma: Can the Outcomes of these Procedures be Compared?. Annals of Surgical Oncology, 2019, 26, 8-9.	0.7	8
557	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	0.5	8
558	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International ComparisonÂof the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	0.7	8

#	Article	IF	CITATIONS
559	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 2021, 28, 6109-6123.	0.7	8
560	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01) Journal of Clinical Oncology, 2013, 31, 9001-9001.	0.8	8
561	Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02 Journal of Clinical Oncology, 2014, 32, 9027-9027.	0.8	8
562	Diagnosis and management of cutaneous melanoma. Australian Journal of General Practice, 2020, 49, 733-739.	0.3	8
563	UNILATERAL PIRIFORMIS SYNDROME IN A PATIENT WITH PREVIOUS MELANOMA. ANZ Journal of Surgery, 1993, 63, 152-153.	0.3	7
564	OCULAR MELANOMA IN CHILDHOOD. ANZ Journal of Surgery, 1993, 63, 729-731.	0.3	7
565	Polypoid melanoma is not rare. British Journal of Dermatology, 1996, 135, 333-334.	1.4	7
566	Internal mammary node metastasis from primary cutaneous melanoma on the anterior chest. ANZ Journal of Surgery, 2005, 75, 723-725.	0.3	7
567	Guidelines for imaging in cutaneous melanoma. Nuclear Medicine Communications, 2008, 29, 877-879.	0.5	7
568	Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Research, 2010, 20, 311-317.	0.6	7
569	Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1039-1045.	1.5	7
570	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. Annals of Surgical Oncology, 2012, 19, 3310-3312.	0.7	7
571	Mitotic rate in melanoma should be recorded as the number of mitoses per mm2 (not per high power) Tj ETQq1	1 0,78431 0.9	4 rgBT /Over
572	Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. Expert Review of Dermatology, 2013, 8, 195-214.	0.3	7
573	<scp>S</scp> entinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in <scp>M</scp> erkel cell carcinoma: A pilot case series. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 353-359.	0.9	7
574	Lymphatic drainage patterns from primary cutaneous tumours of the forehead: Refining the recommendations for selective neck dissection. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2014, 67, 1038-1044.	0.5	7
575	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Patients. Annals of Surgery, 2014, 259, e86.	2.1	7
576	Parallel multicentre randomised trial of a clinical trial question prompt list in patients considering participation in phase 3 cancer treatment trials. BMJ Open, 2017, 7, e012666.	0.8	7

#	Article	IF	CITATIONS
577	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 2021, 108, 550-553.	0.1	7
578	Ultrasound Examination of the Lymphatic Drainage Area and Regional Lymph Nodes in Melanoma Patients with In-Transit Metastases. Annals of Surgical Oncology, 2021, 28, 1625-1631.	0.7	7
579	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. Pathology, 2021, 53, 830-835.	0.3	7
580	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.3	7
581	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e320-e325.	1.8	7
582	Conditional survival estimates for cancer patients. Oncotarget, 2017, 8, 84639-84640.	0.8	7
583	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). European Journal of Surgical Oncology, 2022, 48, 1280-1287.	0.5	7
584	Anomalous Lymphatic Drainage Patterns in Patients with Cutaneous Melanoma. Tumori, 2001, 87, 54-56.	0.6	6
585	Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?. Annals of Surgical Oncology, 2004, 11, 119-121.	0.7	6
586	Topical Diphencyprone Immunotherapy for a Large Primary Melanoma on an Elderly Leg. American Journal of Clinical Dermatology, 2011, 12, 1.	3.3	6
587	Optimum excision margins for melanoma. Lancet, The, 2011, 378, 1608-1610.	6.3	6
588	Evaluation of Incomplete Sentinel Node Biopsy Procedures and Sentinel Node Positivity Rates as Surgical Quality-Assurance Parameters in Melanoma Patients. Annals of Surgical Oncology, 2012, 19, 3919-3925.	0.7	6
589	Publication and Interpretation of Clinical Trial Results: The Need for Caution. Annals of Surgical Oncology, 2012, 19, 1745-1747.	0.7	6
590	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. Oncolmmunology, 2013, 2, e25564.	2.1	6
591	Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 2014, 31, 407-421.	1.7	6
592	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. Annals of Surgical Oncology, 2018, 25, 3476-3482.	0.7	6
593	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. Journal of Surgical Oncology, 2019, 120, 1462-1469.	0.8	6
594	Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. European Journal of Cancer, 2019, 112, 9-11.	1.3	6

JOHN F THOMPSON

#	Article	IF	CITATIONS
595	Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis. Annals of Surgical Oncology, 2020, 27, 561-568.	0.7	6
596	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	0.8	6
597	Melanoma - a management guide for GPs. Australian Family Physician, 2012, 41, 470-3.	0.5	6
598	LIVER RESECTION FOR NEOPLASM. ANZ Journal of Surgery, 1981, 51, 274-279.	0.3	5
599	SURGICAL PROCEDURES FOR MELANOMA IN PUBLIC AND PRIVATE NEW SOUTH WALES HOSPITALS, 2001-2002. ANZ Journal of Surgery, 2006, 76, 318-324.	0.3	5
600	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology, 2008, 53, 345-345.	1.6	5
601	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. Expert Opinion on Medical Diagnostics, 2008, 2, 1-10.	1.6	5
602	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	2.1	5
603	Cellular blue naevus involving the urinary bladder. Pathology, 2012, 44, 664-668.	0.3	5
604	Primary oesophageal melanoma - a case report. World Journal of Surgical Oncology, 2014, 12, 77.	0.8	5
605	Should patients with melanoma brain metastases receive adjuvant whole-brain radiotherapy?. Lancet Oncology, The, 2015, 16, e195-e196.	5.1	5
606	More on Adjuvant Therapy in Resected Melanoma. New England Journal of Medicine, 2018, 378, 1656-1657.	13.9	5
607	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.1	5
608	Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients. European Journal of Surgical Oncology, 2019, 45, 1706-1711.	0.5	5
609	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	0.5	5
610	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	0.5	5
611	Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy. , 2001, 8, 766.		5
612	The prognosis of patients with thick primary melanomas: Is regional lymph node status relevant, and does removing positive regional nodes influence outcome?. , 2002, 9, 719.		5

JOHN F THOMPSON

#	Article	IF	CITATIONS
613	Management of pigmented skin lesions in childhood and adolescence. Australian Journal of General Practice, 2019, 48, 539-544.	0.3	5
614	Management of pigmented skin lesions during pregnancy. Australian Journal of General Practice, 2019, 48, 621-624.	0.3	5
615	Nonocclusive chronic vascular catheterization of conscious unrestrained baboons. Journal of Applied Physiology, 1986, 61, 1955-1958.	1.2	4
616	DECISIONâ€MAKING IN 100 PATIENTS REFERRED TO THE AUSTRALIAN NATIONAL LIVER TRANSPLANTATION UNIT. Australian and New Zealand Journal of Medicine, 1989, 19, 132-137.	0.5	4
617	HAEMODYNAMIC ACTIONS OF A NITRIC OXIDE (EDRF) SYNTHESIS INHIBITOR IN CONSCIOUS BABOONS (Papio)	ſjÆŢQq1 I	l 9 .784314
618	Anaesthetic experience with isolated limb perfusion with melphalan for melanoma. Perfusion (United) Tj ETQq0 0	0ˌrgBT /Ov	verlock 10 T
619	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. , 1998, 82, 1799-1800.		4
620	The influence of HLAâ€A,B and â€DR matching on leucocyte infiltration in renal allografts. Tissue Antigens, 1987, 29, 214-223.	1.0	4
621	In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma. Annals of Surgical Oncology, 2010, 17, 663-664.	0.7	4
622	Sentinel Lymph Node Biopsy for Melanoma: A Plea to Let the Data be Heard. Annals of Surgical Oncology, 2014, 21, 3362-3364.	0.7	4
623	MSLT-l—response of clinical trial investigators. Nature Reviews Clinical Oncology, 2014, 11, 680-680.	12.5	4
624	Sentinel Lymph Node Biopsy: Evolution of the Technique Since the Original Description by Morton et al. in 1992. Critical Reviews in Oncogenesis, 2016, 21, 7-17.	0.2	4
625	Continuing and new roles for surgery in the management of patients with stage IV melanoma. Melanoma Management, 2018, 5, MMT03.	0.1	4
626	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 2019, 20, 477.	0.7	4
627	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. European Journal of Surgical Oncology, 2019, 45, 832-837.	0.5	4
628	Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. American Journal of Surgical Pathology, 2019, 43, 1442-1444.	2.1	4
629	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. Annals of Surgical Oncology, 2019, 26, 315-317.	0.7	4
630	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Annals of Surgical Oncology, 2020, 27, 35-42.	0.7	4

#	Article	IF	CITATIONS
631	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open, 2020, 10, e037857.	0.8	4
632	Surgical Management of Conjunctival Melanomas. JAMA Ophthalmology, 1999, 117, 1098.	2.6	4
633	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	1.3	4
634	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology, 2022, 29, 5937-5945.	0.7	4
635	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). Annals of Surgical Oncology, 2022, , 1.	0.7	4
636	The Problems Associated with Conversion from Azathioprine and Prednisolone to Cyclosporine. Uremia Investigation, 1985, 9, 19-25.	0.1	3
637	NAEVOID BASAL CELL CARCINOMA (GORLIN'S) SYNDROME. ANZ Journal of Surgery, 1993, 63, 413-415.	0.3	3
638	GIANT INFILTRATING LIPOMA OF THE THIGH CAUSING SCIATICA. ANZ Journal of Surgery, 1997, 67, 225-226.	0.3	3
639	Case 2-2007. New England Journal of Medicine, 2007, 356, 285-292.	13.9	3
640	Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. Melanoma Research, 2008, 18, 161-162.	0.6	3
641	Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 2014, 32, 3203-3204.	0.8	3
642	Sentinel node biopsy is now part of routine staging in patients with clinically localized melanoma. ANZ Journal of Surgery, 2014, 84, 701-702.	0.3	3
643	Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients. European Journal of Surgical Oncology, 2017, 43, 2163-2169.	0.5	3
644	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. Pathology, 2018, 50, 364-367.	0.3	3
645	Impact of genomics on the surgical management of melanoma. British Journal of Surgery, 2018, 105, e31-e47.	0.1	3
646	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. Annals of Surgical Oncology, 2019, 26, 4663-4672.	0.7	3
647	Multidisciplinary care of cancer patients: a passing fad or here to stay?. ANZ Journal of Surgery, 2019, 89, 464-465.	0.3	3
648	Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma― Journal of the American Academy of Dermatology, 2023, 88, e25-e26.	0.6	3

JOHN F THOMPSON

#	Article	IF	CITATIONS
649	Letter re: Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma: A multicenter experience. European Journal of Surgical Oncology, 2019, 45, 1121.	0.5	3
650	Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. Annals of Surgical Oncology, 2020, 27, 1970-1977.	0.7	3
651	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Australasian Journal of Dermatology, 2021, 62, 168-176.	0.4	3
652	Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Journal of Surgical Oncology, 1998, 14, 238-247.	1.4	3
653	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2020, , 867-894.		3
654	Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.3	3
655	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15Âmm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	0.6	3
656	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.3	3
657	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	1.3	3
658	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology, 2022, 54, 533-540.	0.3	3
659	Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi. American Journal of Surgical Pathology, 2022, 46, 1048-1059.	2.1	3
660	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. Annals of Surgical Oncology, 2022, 29, 7019-7028.	0.7	3
661	Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. Npj Digital Medicine, 2022, 5, .	5.7	3
662	CYCLOSPORIN A IN OLIGURIC RENAL TRANSPLANT RECIPIENTS. Lancet, The, 1981, 318, 876.	6.3	2
663	Retrieval of organs for transplantation: experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1996, 165, 375-378.	0.8	2
664	Endothelin in Primate Pregnancy and an Experimental Preeclampsia-Like Syndrome. Hypertension in Pregnancy, 1998, 17, 227-240.	0.5	2
665	Letter to the Editor. Annals of Surgical Oncology, 2000, 7, 790-790.	0.7	2
666	Prognostic value of sentinel lymph node biopsy. British Journal of Dermatology, 2007, 157, 405-405.	1.4	2

#	Article	IF	CITATIONS
667	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. European Journal of Surgical Oncology, 2013, 39, 1164-1165.	0.5	2
668	Role of sentinel lymph node biopsy as a staging procedure in patients with melanoma: A critical appraisal. Australasian Journal of Dermatology, 2017, 58, 268-273.	0.4	2
669	When is surgery for metastatic melanoma still the most appropriate treatment option?. Expert Review of Anticancer Therapy, 2018, 18, 943-945.	1.1	2
670	The role of sentinel lymph node biopsy as a staging procedure in patients with melanoma – A critical appraisal. Australasian Journal of Dermatology, 2018, 59, 235-236.	0.4	2
671	ASO Author Reflections: Subungual Melanomas of the Hand Present Diagnostic and Therapeutic Challenges. Annals of Surgical Oncology, 2019, 26, 1044-1045.	0.7	2
672	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. JCO Precision Oncology, 2020, 4, 990-991.	1.5	2
673	ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases. Annals of Surgical Oncology, 2021, 28, 1632-1633.	0.7	2
674	Treatment of in-transit melanoma metastases using intralesional PV-10. Melanoma Research, 2021, 31, 232-241.	0.6	2
675	Organ transplantation and outcomes in patients with a past history of melanoma: A systematic review and metaâ€analysis. Clinical Transplantation, 2021, 35, e14287.	0.8	2
676	Residual melanoma in wide local excision specimens after â€~complete' excision of primary cutaneous in situ and invasive melanomas. Pathology, 2022, 54, 71-78.	0.3	2
677	Desmoplastic and desmoplastic neurotropic melanoma. , 1998, 83, 1128.		2
678	Sentinel Lymph Node Biopsy in Cutaneous Melanoma. , 2008, , 92-110.		2
679	Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role. , 2001, 8, 564.		2
680	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
681	Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!. British Journal of Dermatology, 2022, 186, 205-206.	1.4	2
682	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. JAAD International, 2022, , .	1.1	2
683	Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs. Perfusion (United Kingdom), 1994, 9, 399-404.	0.5	1
684	Latex allergy: An emerging health hazard for operating theatre staff. British Journal of Surgery, 1997, 84, 289-290.	0.1	1

#	Article	IF	CITATIONS
685	Regarding Amelanotic Melanomas. Dermatologic Surgery, 1999, 25, 918.	0.4	1
686	Superior survival of young women with malignant melanoma. American Journal of Surgery, 1999, 178, 358.	0.9	1
687	Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer, 2002, 94, 283-284.	2.0	1
688	Validity of reported melanoma incidence rates in New Zealand. ANZ Journal of Surgery, 2004, 74, 1016-1017.	0.3	1
689	Re: Sydney Melanoma Unit patients and Multicenter Selective Lymphadenectomy Trial protocol. ANZ Journal of Surgery, 2006, 76, 1039-1040.	0.3	1
690	Lymphatic Drainage in Patients with Primary Cutaneous Melanoma - the Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy. Current Medical Imaging, 2006, 2, 261-270.	0.4	1
691	In Reply: Cost-Effectiveness of Sentinel Node Biopsy for Melanoma. Annals of Surgical Oncology, 2009, 16, 2962-2963.	0.7	1
692	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	2.1	1
693	Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours. Australasian Journal of Dermatology, 2015, 56, 227-231.	0.4	1
694	Radioguided Sentinel Lymph Node Mapping and Biopsy in Cutaneous Melanoma. , 2016, , 151-163.		1
695	Doctors' recognition and management of melanoma patients' risk: An Australian population-based study. Cancer Epidemiology, 2016, 45, 32-39.	0.8	1
696	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<Â0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2017, 24, 660-660.	0.7	1
697	Surgical Technique for Open Inguinal Lymphadenectomy. , 2018, , 185-195.		1
698	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. Annals of Surgical Oncology, 2018, 25, 918-919.	0.7	1
699	Isolated Limb Infusion for Recurrent and Locally Metastatic Limb Melanoma. , 2018, , 451-465.		1
700	Appropriate excision margins for cutaneous melanomas. Lancet, The, 2019, 394, 445-446.	6.3	1
701	A History of Melanoma: From Hunter to Morton. , 2019, , 1-19.		1
702	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanomaâ€. Journal of the American Academy of Dermatology, 2019, 80, e21-e22.	0.6	1

#	Article	IF	CITATIONS
703	Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia. BMJ Quality and Safety, 2019, 28, 253-254.	1.8	1
704	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. Australasian Journal of Dermatology, 2019, 60, 75-76.	0.4	1
705	First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?. European Journal of Surgical Oncology, 2020, 46, 272-276.	0.5	1
706	The intriguing association between smoking and reduced melanoma risk. British Journal of Dermatology, 2020, 182, 1080-1080.	1.4	1
707	Evidence-Based Follow-Up Schedules After Primary Cancer Treatment. Annals of Surgical Oncology, 2020, 27, 4067-4069.	0.7	1
708	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	1.3	1
709	Locally advanced melanoma. , 2000, 88, 88.		1
710	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
711	Surgical Management of Distant Melanoma Metastases. , 2020, , 1359-1402.		1
712	Long-termÂcure after complete resection and adjuvant immunotherapy for distant melanoma metastases Journal of Clinical Oncology, 2012, 30, 8534-8534.	0.8	1
713	Regarding Pedunculated Malignant Melanoma. Dermatologic Surgery, 2000, 26, 812.	0.4	1
714	Primary pulmonary melanoma. , 2003, , 641-647.		1
715	Can the demand for cadaver kidneys be met?. Transplantation Proceedings, 1992, 24, 2270-1.	0.3	1
716	Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma. International Journal of Environmental Research and Public Health, 2022, 19, 2331.	1.2	1
717	Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using Tc-labelled antimony sulphide colloid. British Journal of Surgery, 2020, 107, 1773-1779.	0.1	1
718	Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. Clinical Oncology, 2023, 35, e85-e93.	0.6	1
719	Surgery in Patients with Advanced Germ Cell Malignancy following a Clinical Partial Response to Chemotherapy. Journal of Urology, 1984, 131, 412-412.	0.2	0
720	THE RATIONAL USE OF HOMOLOGOUS BLOOD IN ELECTIVE SURGERY. ANZ Journal of Surgery, 1992, 62, 266-269.	0.3	0

721Who should treat patients with primary melanoma?. British Journal of Dermatology, 2005, 153, 459-460.1.40722ABDOMINAL RESECTIONAL SURGERY IN METASTATIC MELANOMA. ANZ Journal of Surgery, 2007, 77, 813-813.0.50723Correct Identification of a sentinal node postselective lymphadenectiony using antinnony levels.0.60724Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.0.80725Sentinel node biopsy for broast cancer: then and now. ANZ Journal of Surgery, 2012, 82, 481-483.0.30726BAP1 mutations, Pathology, 2014, 46, S112.0.100727Has the melanoma information trunami become a maelstroin?. Melanoma Anagement, 2017, 4, 179-182.0.10728Regarding complections following completion lymphadenectomy. European Journal of Surgical0.60729A Las Chertoneal Signature for Rapid Identification of Paor Prognosis Stage III Metastatic Melanoma.0.80720Desmoplastic Melanoma, 2019, 469-481.000721Section of Frastmerre, Cystollitois, and Intransit Metastasis: Incidence, Outcomes, and0.30722New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ0.30723Outsity of Life following Surgical Eccient of EarlyStage Melanoma of the Head and Necch, JAMA0.30724Iverset Melanoma Recurrence, Statellitois, and Intransit Metastasis: Incidence and Maximize0.70725Iverset Melanoma, 2019, 155, 502.000 <t< th=""><th>#</th><th>Article</th><th>IF</th><th>CITATIONS</th></t<>	#	Article	IF	CITATIONS
723Correct identification of a sentinel node postselective lymphadenectomy using antimony levels.0.60724Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.0.80725Sentinel node biopsy for breast cancer: then and now. ANZ Journal of Surgery, 2012, 82, 481-483.0.30726IJ, Peritoneal epithelioid mesothelioma in a patient with metastatic melanoma - an association seen in BAP1 nutations. Pathology, 2014, 46, S112.0.10727Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.0.10728Regarding complications following completion lymphadenectomy. European Journal of Surgical Oncology, 2017, 43, 2374-2375.0.60729Protectin Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Protectin Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Desincolagy, 2017, 43, 2374-2375.0.30730Desincoplastic Melanoma, 2019, 469-481.00731Local Melanoma Recurrence, Satellitosis, and In transit Metastasis: Incidence, Outcomes, and Selection of Freetment Options, 2019, 1-28.0.30732New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Permatology, 2019, 155, 502.0.30733Quality of Life Following Surgical Excision of Early Stage Melanoma of the Head and Neck, JAMA Vermatology, 2019, 155, 502.0.30734Kower Lip Reconstruction Revisited. Technical Solutions to Prevent Oral Incontinence and Maximize Vermatology, 2020, 146, 515-6917.0.8	721	Who should treat patients with primary melanoma?. British Journal of Dermatology, 2005, 153, 459-460.	1.4	0
725 Melanoma Research, 2008, 15, 365-366. 00 724 Reply to 1. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317. 0.8 0 725 Sentinel node biopsy for breast cancer: then and now, ANZ Journal of Surgery, 2012, 82, 451-483. 0.3 0 726 17. Peritoneal epithelioid mesethelioma in a patient with metastatic melanoma - an association seen in BAP1 mutations. Pathology, 2014, 46, 5112. 0.1 0 727 Has the melanoma Information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182. 0.1 0 728 Regarding complications following completion lymphadenectomy. European Journal of Surgical 0.3 0 729 A 145eProtein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. 0.8 0 730 Desmoplastic Melanoma. 2019, 469-481. 0 0 731 Local Melanoma Recurrence, Satellitosis, and in-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019, 128. 0 0 732 New treatment paradigms for clinical by apparent metastatic melanoma in regional lymph nodes. ANZ 0.3 0 733 Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA 2.0 0 732 New treatment paradigms fo	722	ABDOMINAL RESECTIONAL SURGERY IN METASTATIC MELANOMA. ANZ Journal of Surgery, 2007, 77, 813-813.	0.3	0
725Sentinel node blopsy for breast cancer: then and now. ANZ Journal of Surgery, 2012, 82, 481-483.0.3072617. Peritoneal epithelioid mesorthelioma in a patient with metastatic melanoma - an association seen in DAP1 mutations. Pathology, 2014, 46, 5112.0.30727Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.0.10728Regarding complications following completion lymphadenectomy. European Journal of Surgical Oncology, 2017, 43, 2374-2375.0.50729A 1436Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.0.80730Desmoplastic Melanoma., 2019, , 469-481.0731Local Melanoma Recurrence, Satellitods, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options, 2019, 128.0.30732New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Pormal of Surgery, 2013, 89, 1187-1189.0.30734Coulty of Life Following Europical Excision of Early-Stage Melanoma of the Head and Neck, JAMA Pormatology, 2019, 155, 502.0.70735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Surgery, 2020, 213, 400.0.80736New Australian Dianoma management guidelines: the patient perspective. Medical Journal of 	723	Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. Melanoma Research, 2008, 18, 365-366.	0.6	0
726J.7. Peritoneal epithelioid mesothelioma in a patient with metastatic melanoma - an association seen in BAP1 mutations. Pathology, 2014, 46, 5112.0.30727Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.0.10728Regarding complications following completion lymphadenectomy. European Journal of Surgical Oncology, 2017, 43, 2374-2375.0.50729A 143€Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 2019, 12, 1700094.0.80730Desmoplastic Melanoma , 2019, 469-481.00731Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and 	724	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	0.8	0
P28BAP1 mutations. Pathology, 2014, 46, S112.0.30727Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.0.10728Regarding complications following completion lymphadenectomy. European Journal of Surgical Oncology, 2017, 43, 2374-2375.0.50729A 1446Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.0.80730Desmoplastic Melanoma., 2019, , 469-481.0731Local Melanoma Recurrence, Satellitosis, and in-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019, , 1-28.0732New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Journal of Surgery, 2019, 89, 1187-1189.0.30734Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Wermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.0.70735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.0.80733In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow. No. Research and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgeral Oncology, 2021, 28, 6915-6917.0.70	725	Sentinel node biopsy for breast cancer: then and now. ANZ Journal of Surgery, 2012, 82, 481-483.	0.3	0
728Regarding complications following completion lymphadenectomy. European Journal of Surgical Oncology, 2017, 43, 2374-2375.0.50729A 14â€Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 2018, 12, 1700094.0.80730Desmoplastic Melanoma ., 2019, , 469-481.0731Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019, , 1-28.0732New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Durnal of Surgery, 2019, 89, 1187-1189.0.30733Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502.0.70734Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermillion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.0.80735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917.0.70	726		0.3	0
728 Oncology, 2017, 43, 2374-2375. 0.3 0 729 A 14â€Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. Proteomics - Clinical Applications, 2018, 12, 1700094. 0.8 0 730 Desmoplastic Melanoma., 2019,, 469-481. 0 731 Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019,, 1-28. 0 732 New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Journal of Surgery, 2019, 89, 1187-1189. 0.3 0 733 Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502. 0.7 0 734 Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e. 0.7 0 735 New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400. 0.8 0 736 In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?, Annals of Surgical Oncology, 2021, 28, 6915-6917. 0.7 0	727	Has the melanoma information tsunami become a maelstrom?. Melanoma Management, 2017, 4, 179-182.	0.1	0
129 Proteomics - Clinical Applications, 2018, 12, 1700094. 0.8 0 730 Desmoplastic Melanoma, 2019, ,469-481. 0 731 Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019, ,1-28. 0 732 New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Journal of Surgery, 2019, 89, 1187-1189. 0.3 0 733 Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502. 2.0 0 734 Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e. 0.7 0 735 New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400. 0.8 0 736 In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917. 0.7 0	728		0.5	0
731Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options., 2019, , 1-28.0732New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Journal of Surgery, 2019, 89, 1187-1189.0.30733Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502.2.00734Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.0.70735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.0.80736In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917.0.70	729		0.8	0
731 Selection of Treatment Options., 2019, 1-28. 0 732 New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ 0.3 0 732 Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA 2.0 0 733 Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA 2.0 0 734 Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e. 0.7 0 735 New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400. 0.8 0 736 In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917. 0.7 0	730	Desmoplastic Melanoma. , 2019, , 469-481.		0
732Journal of Surgery, 2019, 89, 1187-1189.0.30733Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA2.00734Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.0.70735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.0.80736In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917.0.70	731	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. , 2019, , 1-28.		0
733Dermatology, 2019, 155, 502.2.00734Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.0.70735New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.0.80736In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917.0.70	732	New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. ANZ Journal of Surgery, 2019, 89, 1187-1189.	0.3	0
734 Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e. 0.7 0 735 New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400. 0.8 0 736 In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive O.7 0.7 0	733	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502.	2.0	0
733 Australia, 2020, 213, 400. 0.8 0 In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection 736 Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive 0.7 0 Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917. 0.7 0	734		0.7	0
736 Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive 0.7 0 Follow-Up?. Annals of Surgical Oncology, 2021, 28, 6915-6917.	735	New Australian melanoma management guidelines: the patient perspective. Medical Journal of Australia, 2020, 213, 400.	0.8	0
	736	Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive	0.7	0
The worse survival outcomes reported for melanoma patients having sentinel node biopsy after 737 lymphoscintigraphy the previous day do not appear to be due to overnight migration of 0.5 0 Tc99m-nanocolloid tracer. European Journal of Surgical Oncology, 2021, 47, 2450-2453.	737	The worse survival outcomes reported for melanoma patients having sentinel node biopsy after lymphoscintigraphy the previous day do not appear to be due to overnight migration of Tc99m-nanocolloid tracer. European Journal of Surgical Oncology, 2021, 47, 2450-2453.	0.5	0

Hepatic surgery for metastatic melanoma. , 2003, , 505-513.

#	Article	IF	CITATIONS
739	Melanoma of the urogenital tract. , 2003, , 636-640.		0
740	Primary invasive melanoma on the head and neck: Distribution, ultraviolet exposure and histological subtype in 1,298 Australian patients. Journal of Clinical Oncology, 2007, 25, 8541-8541.	0.8	0
741	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. Journal of Clinical Oncology, 2007, 25, 8509-8509.	0.8	0
742	Radiation in the Management of Primary and Regional Merkel Cell Carcinoma. Modecular Medicine and Medicinal, 2010, , 229-238.	0.4	0
743	Isolierte arterielle Infusion von ExtremitÃ e en. , 2013, , 313-325.		0
744	Specialized Cancer Procedures and Surgery. , 2014, , 201-218.		0
745	Latex allergy: An emerging health hazard for operating theatre staff. British Journal of Surgery, 1997, 84, 289-290.	0.1	0
746	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials Journal of Clinical Oncology, 2015, 33, e20011-e20011.	0.8	0
747	Isolated Limb Infusion. , 2016, , 375-390.		0
748	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy Journal of Clinical Oncology, 2017, 35, 51-51.	0.8	0
749	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance Journal of Clinical Oncology, 2018, 36, 9518-9518.	0.8	0
750	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
751	Treatment of Primary Melanomas. , 2019, , 1-22.		0
752	Biopsy of the Sentinel Lymph Node. , 2019, , 1-32.		0
753	Models for Predicting Melanoma Outcome. , 2019, , 1-16.		0
754	Surgical Management of Distant Melanoma Metastases. , 2019, , 1-44.		0
755	Desmoplastic Melanoma. , 2019, , 1-13.		0

#	Article	IF	CITATIONS
757	A History of Melanoma: From Hunter to Morton. , 2020, , 1457-1475.		0
758	Models for Predicting Melanoma Outcome. , 2020, , 299-314.		0
759	Treatment of Primary Melanomas. , 2020, , 573-594.		0
760	Axillary and Epitrochlear Lymph Node Dissection for Melanoma. , 2020, , 657-667.		0
761	Lymphoscintigraphy in Patients with Melanoma. , 2020, , 205-237.		0
762	Biopsy of the Sentinel Lymph Node. , 2020, , 239-270.		0
763	Competing risks analysis with missing cause-of-failure—penalized likelihood estimation of cause-specific Cox models. Statistical Methods in Medical Research, 2022, , 096228022110702.	0.7	0
764	Donor factors and liver transplantation. Transplantation Proceedings, 1992, 24, 2083-4.	0.3	0
765	Anomalous lymphatic drainage patterns in patients with cutaneous melanoma. Tumori, 2001, 87, S54-6.	0.6	0
766	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research, 2022, Publish Ahead of Print, .	0.6	0